Peter Ruth Selected Research

Cyclic GMP-Dependent Protein Kinase Type I

8/2008	cGMP produced by NO-sensitive guanylyl cyclase essentially contributes to inflammatory and neuropathic pain by using targets different from cGMP-dependent protein kinase I.
2/2008	Cysteine-rich protein 2, a novel downstream effector of cGMP/cGMP-dependent protein kinase I-mediated persistent inflammatory pain.
3/2004	Reduced inflammatory hyperalgesia with preservation of acute thermal nociception in mice lacking cGMP-dependent protein kinase I.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Peter Ruth Research Topics

Disease

9	Neoplasms (Cancer) 01/2022 - 01/2013
8	Pain (Aches) 01/2022 - 05/2005
6	Wounds and Injuries (Trauma) 01/2016 - 07/2007
5	Glioblastoma (Glioblastoma Multiforme) 01/2022 - 10/2011
4	Infarction (Infarctions) 01/2022 - 12/2010
4	Intellectual Disability (Idiocy) 12/2021 - 01/2013
4	Hyperalgesia 05/2005 - 10/2002
3	Breast Neoplasms (Breast Cancer) 01/2022 - 01/2017
3	Myocardial Infarction 01/2022 - 12/2017
3	Deafness (Deaf Mutism) 05/2013 - 08/2004
2	Atherosclerosis 01/2022 - 08/2015
2	Brain Neoplasms (Brain Tumor) 01/2022 - 03/2016
2	Neoplasm Metastasis (Metastasis) 01/2019 - 10/2016
2	Reperfusion Injury 12/2017 - 01/2014
2	Body Weight (Weight, Body) 12/2016 - 11/2008
2	Epilepsy (Aura) 01/2016 - 12/2006
2	Autistic Disorder (Autism) 07/2015 - 01/2013
2	Neuralgia (Stump Neuralgia) 01/2015 - 08/2008
2	Hypoxia (Hypoxemia) 01/2014 - 08/2009
2	Hearing Loss (Hearing Impairment) 10/2012 - 08/2004
2	Chronic Obstructive Pulmonary Disease (COPD) 04/2011 - 09/2010
2	Hyperaldosteronism (Conn Syndrome) 05/2010 - 07/2005
2	Inflammation (Inflammations) 05/2005 - 03/2004
1	Disease Progression 01/2022
1	Muscle Hypotonia (Hypotonia) 09/2021
1	Seizures (Absence Seizure) 01/2020
1	Myotonia 01/2020
1	Carcinogenesis 01/2019
1	Color Vision Defects (Color Blindness) 12/2018
1	Cone Dystrophy 12/2018
1	Noise-Induced Hearing Loss (Acoustic Trauma) 01/2018
1	Memory Disorders (Memory Loss) 01/2018
1	Ischemia 12/2017
1	Weight Gain 12/2016
1	Obesity 12/2016

Drug/Important Bio-Agent (IBA)

18	Large-Conductance Calcium-Activated Potassium Channels (Maxi-K Channels)IBA 01/2022 - 07/2005
8	Proteins (Proteins, Gene)FDA Link 01/2022 - 05/2005
5	Potassium Channels (Potassium Channel)IBA 01/2022 - 08/2004
5	Calcium-Activated Potassium Channels (Calcium-Activated Potassium Channel)IBA 12/2017 - 08/2009
4	Messenger RNA (mRNA)IBA 01/2022 - 09/2015
3	paxillineIBA 01/2020 - 10/2011
3	PotassiumIBA 01/2020 - 08/2004
3	Peptide Hydrolases (Proteases)FDA Link 08/2010 - 07/2007
3	Collagen Type I (Type I Collagen)IBA 08/2010 - 07/2007
3	Cyclic GMP-Dependent Protein Kinase Type IIBA 08/2008 - 03/2004
3	Formaldehyde (Formol)FDA Link 05/2005 - 03/2003
2	Cysteine (L-Cysteine)FDA Link 01/2022 - 02/2008
2	Capsaicin (Zostrix)FDA Link 01/2022 - 01/2022
2	Pharmaceutical PreparationsIBA 12/2021 - 12/2016
2	BAY 58-2667IBA 09/2021 - 01/2018
2	Brain-Derived Neurotrophic Factor (BDNF)IBA 01/2018 - 01/2018
2	Soluble Guanylyl CyclaseIBA 01/2018 - 12/2017
2	Glucose (Dextrose)FDA LinkGeneric 12/2016 - 08/2009
2	Interleukin-6 (Interleukin 6)IBA 12/2016 - 08/2010
2	AMP-Activated Protein KinasesIBA 07/2015 - 10/2012
2	polihexanideIBA 01/2015 - 09/2009
2	RoflumilastIBA 04/2011 - 09/2010
2	Collagenases (Collagenase)FDA Link 01/2011 - 07/2007
2	CytokinesIBA 08/2010 - 08/2009
2	CollagenIBA 08/2009 - 07/2007
2	ZymosanIBA 05/2005 - 03/2004
1	Apolipoproteins E (ApoE)IBA 01/2022
1	mitochondrial K(ATP) channelIBA 01/2022
1	NestinIBA 01/2022
1	Tamoxifen FDA LinkGeneric 01/2022
1	Somatostatin (Somatotropin Release-Inhibiting Factor)IBA 01/2022
1	allyl isothiocyanateIBA 01/2022
1	Nitroprusside (Sodium Nitroprusside)FDA LinkGeneric 09/2021
1	Carbachol (Carbastat)FDA Link 09/2021
1	Chloride Channels (Chloride Channel)IBA 01/2020
1	9-anthroic acidIBA 01/2020
1	Pentylenetetrazole (Metrazol)IBA 01/2020
1	Docetaxel (Taxotere)FDA Link 09/2019
1	Doxorubicin (Adriamycin)FDA LinkGeneric 09/2019
1	Fluorouracil (Carac)FDA LinkGeneric 09/2019
1	Cyclophosphamide (Cytoxan)FDA LinkGeneric 09/2019
1	Cyclic NucleotidesIBA 12/2018
1	Ion Channels (Ion Channel)IBA 12/2018
1	Retinaldehyde (Retinal)IBA 12/2018
1	1- (3,5- bis(trifluoromethyl)phenyl)- 3- (4- bromo- 2- (1H- tetrazol- 5- yl)phenyl)thioureaIBA 01/2018
1	Tadalafil (Cialis)FDA Link 01/2018
1	Guanosine Monophosphate (5' Guanylic Acid)IBA 01/2018
1	Type 5 Cyclic Nucleotide PhosphodiesterasesIBA 01/2018
1	Sildenafil Citrate (Viagra)FDA Link 01/2018
1	ParvalbuminsIBA 01/2018
1	Cyclic GMP-Dependent Protein Kinases (Protein Kinase G)IBA 12/2017
1	Intermediate-Conductance Calcium-Activated Potassium ChannelsIBA 10/2017
1	ErbB Receptors (EGF Receptor)IBA 01/2017
1	Tumor Viral Antigens (Large T Antigen)IBA 01/2017
1	Dietary Fats (Dietary Fat)IBA 12/2016
1	Uncoupling Protein 1IBA 12/2016
1	ChemokinesIBA 03/2016
1	Fura-2 (Fura 2)IBA 03/2016

Therapy/Procedure

10	Therapeutics 01/2022 - 09/2015
4	Radiotherapy 09/2019 - 01/2013
2	Transplantation 09/2019 - 01/2017
2	Drug Therapy (Chemotherapy) 09/2019 - 12/2016
1	Isogeneic Transplantation 01/2022
1	Aftercare (After-Treatment) 09/2019
1	Ischemic Postconditioning 01/2018